If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
248
results.
Updated on
19/04/2026 [07:16:00]
Results 225 to 248 of 248
Absstract of: US20260049276A1
The present invention relates to methods for deriving human hematopoietic progenitors, primitive macrophages, and microglial cells from human pluripotent stem cells. In particular, provided herein are highly efficient and reproducible methods of obtaining human primitive macrophages and microglia from human pluripotent stem cells, where the primitive macrophages and microglia can be suitable for clinically relevant therapeutic applications.
Absstract of: US20260049985A1
A composition comprising gold nanoparticles which are linked to polyclonal antibodies. The composition may be used to detect the presence of a target which binds to the polyclonal antibody in solution. The binding of the target to the polyclonal antibody triggers a self-assembly of the polyclonal antibody and the gold nanoparticles. This self-assembly of the polyclonal antibody and the gold nanoparticles triggers a colour change in the surface plasmon of the gold nanoparticles which indicates the presence of the target.
Absstract of: US20260049128A1
0000 Anti-hog transcobalamin-1 (TCN1) monoclonal antibodies are disclosed, along with epitopes recognized by same. Also disclosed are kits containing the monoclonal antibodies and methods of producing the antibodies. Further disclosed are methods of using the monoclonal antibodies, such as (but not limited to) in methods of estimating and/or removing TCN1 from hog intrinsic factor preparations.
Absstract of: US20260049305A1
0000 Cas-protein-ready tau biosensor cells, CRISPR/Cas synergistic activation mediator (SAM)-ready tau biosensor cells, and methods of making and using such cells to screen for genetic modifiers of tau seeding or aggregation are provided. Reagents and methods for sensitizing such cells to tau seeding activity or tau aggregation or for causing tau aggregation are also provided.
Absstract of: AU2026200694A1
Methods of measuring the amount of singly- or multiply-phosphorylated p217+ tau protein in a sample are provided. Methods of detecting or diagnosing tauopathies, methods of determining the effectiveness of a treatment of a tauopathy, and methods of determining whether a subject is suitable for anti-p217+ tau antibody therapy are also provided. Also described are antibodies for use in the methods and kits comprising the antibodies. an a n
Absstract of: WO2026039691A2
Provided herein are compositions, methods, and kits useful for addressing the shortcomings of previous disclosures for the synthesis, evaluation, and uses of disease-specific pathogenic fibrils. In aspects, the disease-specific pathogenic fibril is a disease-specific pathogenic tau fibril.
Absstract of: WO2026038520A1
The present invention provides a technology for testing for and diagnosing various diseases by supplementing and recovering extracellular vesicles (EVs) by a simple method and analyzing the characteristics of the recovered extracellular vesicles (EVs) rapidly and accurately. This method for testing for disease comprises: a step (a) for supplementing and/or recovering a plurality of extracellular vesicles from a biological sample of a test subject; a step (b) for detecting the plurality of supplemented and/or recovered extracellular vesicles; and a step (c) for analyzing a pattern of the detected extracellular vesicles. Step (a) includes: a step (a1) for causing the extracellular vesicles to be adsorbed to a solid-phase carrier containing a base material and an ion exchanger and having the ability to adsorb extracellular vesicles; a step (a2) for labeling the extracellular vesicles adsorbed to the solid-phase carrier; and a step (a3) for washing the labeled extracellular vesicles while in the state of being adsorbed to the solid-phase carrier.
Absstract of: WO2026039578A1
Disclosed herein are methods for treating a disease or disorder of the central or peripheral nervous system by administering to a subject in thereof an agent capable of modulating the activity or expression of bone morphogenetic protein and activin membrane-bound inhibitor (BAMBI). Additionally, methods for screening agents capable of modulating the activity or expression of BAMBI are disclosed.
Absstract of: WO2026039731A1
The present disclosure is directed to human recombinant antibodies and analysis of antibody genetics in subjects having radiologically isolated syndrome to determine risk of developing multiple sclerosis. The present disclosure is further directed to methods of evaluating said antibodies for pathogenic agents or neuroprotective candidates.
Absstract of: WO2026039757A1
Disclosed are methods, compositions, and kit, systems, and platforms for detecting anesthetic induced neurotoxicity (AIN). The inventors discovered several biomarkers indicative of AIN, e.g., in pediatric subjects. The disclosed methods detect at least one of the disclosed biomarkers including, but not limited to, ARHGAP8, BAG1, FUT11, IL17RC, LRRC36, MPO, ACTN1, PTPRN2, CKMT1B, SERINC1, BAG3, DCDC2C, FAM120A, GAPVD1, KAT2A, NUP188, RHBDD3, RTEL1, RWDD4, SCNN1D, SHC2, CCDC144NL-AS1, DHRS4-AS1, G061722, HRAT5, LINC00408, LINC00652, LINC01023, XLOC_004632, G038394, LACTB2-AS1, LINC00685, or LIPE-AS1.
Absstract of: WO2026038996A1
The present invention relates to the field of proteomics and analytical biochemistry, specifically to methods for detecting and quantifying protein tyrosine phosphatases (PTPs) in samples. More particularly, the present invention relates to the use of high-throughput liquid chromatography–tandem mass spectrometry (LC-MS/MS) methods employing scheduled Parallel Reaction Monitoring (sPRM) for determining both expression levels and enzymatic activity of individual PTP isoforms, and the use of such methods in the diagnosis, prognosis, and monitoring of disease and conditions associated with aberrant PTP expression and/or activity levels.
Absstract of: US20260049978A1
A cell-based screening system and method for identifying compounds that selectively modulate the expression of CAG repeat-containing RNA associated with spinocerebellar ataxias and related disorders. The system comprises a human HEK293T cell line engineered to co-express two reporter constructs: a CAG repeat-expanded polyglutamine-nanoluciferase fusion protein with at least 60 CAG repeats, and a control firefly luciferase with no CAG repeats. Each construct contains a unique probe-binding sequence downstream of the repeat region, enabling independent quantification via multiplex RT-qPCR with fluorescent probes, as well as dual luciferase assays. The cell line is optimized for high-throughput screening to identify therapeutic compounds that reduce pathogenic CAG repeat RNA levels while sparing control transcripts. The invention further encompasses methods for screening, validating, and identifying candidate therapeutics for CAG expansion disorders, including spinocerebellar ataxias and Huntington's disease.
Absstract of: WO2026039416A1
Described herein are detecting methods for conformational disease, aging and proteinopathies, by measuring the presence of b-isox-precipitates and the levels of b-isox-captured proteins in biofluids of healthy individuals and patients. Research identified additional biomarkers, which made it possible to detect, diagnose or treat, a human disease in a human subject by, with or without adding an isoxazole to an obtained biofluid sample, detecting the biomarker. Use of b-iso and/or biomarkers for diagnosing the disease are made possible.
Absstract of: US20260048083A1
A method for treating Alzheimer's disease is disclosed. The method comprises identifying a subject and treating the subject with expanded natural killer cells (NKs). A composition for treating Alzheimer's disease is also disclosed.
Absstract of: US20260048090A1
The present disclosure relates to an engineered M13 bacteriophage displaying amyloidogenic peptide motifs from amyloid beta 42 (Aβ42) at its surface. The present disclosure further relates to the use of the disclosed engineered M13 bacteriophage for detecting early species of Aβ, namely oligomeric and fibrillar Aβ, and preventing its aggregation promoting the inhibition of the progression of Alzheimer's disease and thus contributing to the treatment of this neurodegenerative disorder.
Absstract of: US20260048134A1
Disclosed herein is a delivery agent that facilitates effective delivery of drugs and other compounds across lipid layers. The delivery agent disclosed herein provides lipid solubility under selected conditions and aqueous solubility under other conditions, and can effectively deliver compounds into the cell cytosol. The disclosed delivery agent also avoids deleterious interactions with serum and thus provide efficient in vivo delivery of therapeutic agents.
Absstract of: US20260049998A1
0000 The present disclosure provides a whole blood, protein-based diagnostic test for presence and evaluation of aneurysm status. Further, the present disclosure relates to methods of treating aneurysms.
Absstract of: US20260048104A1
0000 In some aspects, the disclosure relates to compositions and methods useful for the diagnosis and treatment of neurodegenerative diseases, such as leukodystrophies (e.g., Canavan Disease). In some embodiments, the methods comprise administering to a subject an N-acetylaspartate (NAA)-depleting agent or an N-acetylaspartate (NAA)-depleting agent based upon the subject's metabolic profile.
Absstract of: AU2024249796A1
The present invention relates to protein markers relevant to mild cognitive impairment (MCI) and Alzheimer's disease (AD), especially those detectable in blood samples. Thus, methods and compositions are provided for risk assessment and early diagnosis of MCI and AD based on the analysis of these protein markers. Further provided are methods and compositions useful for evaluating the efficacy of a therapy for MCI or AD.
Absstract of: EP4697009A1
0001 The present invention includes the steps of: causing a fluid sample containing an analyte to flow over a substrate having an array of microchambers formed on a surface thereof, with a first capture substance that specifically binds to the analyte immobilized in the microchambers; binding the analyte to the first capture substance in each microchamber of the array of microchambers; causing a second capture substance, which specifically binds to the analyte and binds to a signal-generating substance, to flow over the substrate to react the analyte with the second capture substance; causing the signal-generating substance to flow over the substrate to bind to the second capture substance; causing a substrate solution, which reacts with the signal-generating substance to generate a fluorescence signal, to flow over the substrate; causing a hydrophobic solvent to flow over the substrate to remove the substrate solution present outside the microchambers when the signal-generating substance and the substrate solution react in the microchambers; and counting and detecting the number of microchambers in which the fluorescence signal is generated.
Absstract of: EP4697023A2
0001 Disclosed herein are methods that aid in the hyperacute diagnosis and evaluation of a human subject that has sustained or may have sustained an injury to the head, such as mild or moderate, severe, or moderate to severe traumatic brain injury (TBI), using an early biomarker, such as ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) glial fibrillary acidic protein (GFAP), or a combination thereof. Also disclosed here are methods that aid in the hyperactite determination of whether a human subject that has sustained an injury or may have sustained to the head would benefit from and thus receive a head computerized tomography (CT) scan based on the levels of UCH-L.1. These methods involve detecting levels of early biomarker, such as ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) glial fibrillary acidic protein (GFAP), or a combination thereof, in samples taken from a human subject at a time point within about 2 hours, such as about 10, 12, or 20 minutes, after the subject has sustained or may have sustained an injury to the head.
Absstract of: EP4697021A2
An embodiment according to the present invention provides a kit or device for detection of dementia, and a method for detecting dementia. An embodiment according to the present invention relates to: a kit or device for detection of dementia, including a nucleic acid(s) capable of specifically binding to an miRNA(s) or a complementary strand(s) thereof in a sample from a subject; and a method for detecting dementia, including measuring the miRNA(s) in vitro.
Nº publicación: JP2026027295A 18/02/2026
Applicant:
プレジデントアンドフェローズオブハーバードカレッジ
Absstract of: CA2106077A1
2106077 9216902 PCTABS00016 A data processing pension plan monitor (40) is directed specifically to the management and controlled access of pensionbacked credit (AC). This system permits pension plan participants to establish a line of credit (LOC), based on their vested interest in a sponsored pension plan (10). This LOC is thereafter systematically applied to a plurality of account (80, 90), each permitted selected credit card (90) and/or check writing privileges. The charges associated with the credit accessed are paid back to the pensioner, thereby retaining certain tax deferred privileges while permitting access to the accumulated funds.
BOPI
Electronic site
